Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	48.54B
Revenue (ttm)	3.72B
Net Income (ttm)	395.46M
Shares Out	1.11B
EPS (ttm)	0.35
PE Ratio	125.03
Forward PE	84.15
Dividend	0.42 (0.97%)
Ex-Dividend Date	Jan 24, 2025

Volume	3,746,600
Average Volume	5,913,504
Open	45.99
Previous Close	42.92
Day's Range	42.53 - 45.99
52-Week Range	25.48 - 47.50
Beta	-0.03
RSI	56.15
Earnings Date	Apr 12, 2025

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,337
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2024, SHE:002653's revenue was 3.72 billion, an increase of 10.92% compared to the previous year's 3.36 billion. Earnings were 395.46 million, an increase of 34.00%.